CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+7.53%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
+$162M
(+18%)
Cap. Flow
+$137M
Cap. Flow
% of AUM
12.79%
Top 10 Holdings %
Top 10 Hldgs %
37.33%
Holding
532
New
105
Increased
323
Reduced
47
Closed
36
Top Buys
| 1 |
Apple
AAPL
|
$9.9M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$7.06M |
| 3 |
NVIDIA
NVDA
|
$6.46M |
| 4 |
Microsoft
MSFT
|
$6.23M |
| 5 |
ProShares Ultra Gold
UGL
|
$5.73M |
Top Sells
| 1 |
Alibaba
BABA
|
$5.72M |
| 2 |
GSK
GSK
|
$5.14M |
| 3 |
Pinduoduo
PDD
|
$3.46M |
| 4 |
Procter & Gamble
PG
|
$2.91M |
| 5 |
Synopsys
SNPS
|
$2.45M |
Sector Composition
| 1 | Technology | 38.06% |
| 2 | Healthcare | 25.43% |
| 3 | Consumer Discretionary | 12.38% |
| 4 | Communication Services | 10.24% |
| 5 | Financials | 3.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Merus
MRUS
$5.1B
| $610K | 0.06% |
14,517
+1,398
| +11% | +$58.8K |
|
|
HSAI
227
Hesai Group
HSAI
$3.52B
| $608K | 0.06% |
44,000
+14,500
| +49% | +$200K |
|
228
Kraft Heinz
KHC
$32.3B
| $604K | 0.06% |
19,678
+4,342
| +28% | +$133K |
|
229
TJX Companies
TJX
$155B
| $600K | 0.06% |
4,970
+3,970
| +397% | +$480K |
|
230
Amicus Therapeutics
FOLD
$2.46B
| $597K | 0.06% |
63,358
+6,314
| +11% | +$59.5K |
|
231
Janux Therapeutics
JANX
$1.44B
| $596K | 0.06% |
11,128
+1,095
| +11% | +$58.6K |
|
232
Twist Bioscience
TWST
$1.55B
| $585K | 0.05% |
12,586
+1,318
| +12% | +$61.2K |
|
233
GE HealthCare
GEHC
$34.6B
| $581K | 0.05% |
7,435
+1,643
| +28% | +$128K |
|
234
Coca-Cola Europacific Partners
CCEP
$40.4B
| $575K | 0.05% |
7,492
+1,667
| +29% | +$128K |
|
235
Biohaven
BHVN
$1.68B
| $575K | 0.05% |
+15,396
| New | +$575K |
|
236
Vericel Corp
VCEL
$1.72B
| $575K | 0.05% |
10,466
+1,036
| +11% | +$56.9K |
|
237
Penumbra
PEN
$11B
| $573K | 0.05% |
+2,414
| New | +$573K |
|
|
SWTX
238
DELISTED
SpringWorks Therapeutics
SWTX
| $570K | 0.05% |
15,773
+1,488
| +10% | +$53.8K |
|
239
Vera Therapeutics
VERA
$1.54B
| $568K | 0.05% |
13,427
+2,882
| +27% | +$122K |
|
240
Legend Biotech
LEGN
$6.66B
| $564K | 0.05% |
17,320
+1,609
| +10% | +$52.4K |
|
241
Kymera Therapeutics
KYMR
$3.11B
| $552K | 0.05% |
13,733
+1,311
| +11% | +$52.7K |
|
242
Recursion Pharmaceuticals
RXRX
$2.01B
| $547K | 0.05% |
80,943
+28,038
| +53% | +$190K |
|
243
Edgewise Therapeutics
EWTX
$1.64B
| $536K | 0.05% |
20,077
+2,042
| +11% | +$54.5K |
|
244
Take-Two Interactive
TTWO
$44.2B
| $526K | 0.05% |
2,858
+635
| +29% | +$117K |
|
245
Diageo
DEO
$61.3B
| $523K | 0.05% |
4,117
| – | – |
|
246
Amneal Pharmaceuticals
AMRX
$3.02B
| $520K | 0.05% |
+65,698
| New | +$520K |
|
247
DexCom
DXCM
$31.6B
| $512K | 0.05% |
6,580
+1,274
| +24% | +$99.1K |
|
248
Dyne Therapeutics
DYN
$2.02B
| $508K | 0.05% |
21,575
+2,265
| +12% | +$53.4K |
|
249
Domino's
DPZ
$15.7B
| $506K | 0.05% |
1,206
-1,211
| -50% | -$508K |
|
250
NewAmsterdam Pharma
NAMS
$3.04B
| $503K | 0.05% |
+19,589
| New | +$503K |
|